

# osteocalcin siRNA (h): sc-40790

## BACKGROUND

Bone  $\gamma$ -carboxyglutamic acid (Gla) protein, known as BGLAP, BGP or osteocalcin, is an abundant, non-collagenous protein component of bone that is produced by osteoblasts. In mice, osteocalcin is composed of a cluster of three genes known as OG1, OG2 and ORG, all of which can be found within a 23 kb span of genomic DNA. Human osteocalcin is a highly conserved, 46-50 amino acid, single chain protein that contains three vitamin K-dependent  $\gamma$ -carboxyglutamic acid residues. Osteocalcin appears transiently in embryonic bone at the time of mineral deposition, where it binds to hydroxyapatite in a calcium-dependent manner. In addition, osteocalcin is one of the most abundant, non-collagenous proteins found in mineralized adult bone. Genetic variation at the osteocalcin locus on chromosome 1q impacts postmenopause bone mineral density (BMD) levels and may predispose some women to osteoporosis.

## REFERENCES

- Chenu, C., et al. 1994. Osteocalcin induces chemotaxis, secretion of matrix proteins and calcium-mediated intracellular signaling in human osteoclast-like cells. *J. Cell Biol.* 127: 1149-1158.
- Kasai, R., et al. 1994. Production and characterization of an antibody against the human bone GLA protein (BGP/osteocalcin) propeptide and its use in immunocytochemistry of bone cells. *Bone Miner.* 25: 167-182.
- Desbois, C., et al. 1994. The mouse osteocalcin gene cluster contains three genes with two separate spatial and temporal patterns of expression. *J. Biol. Chem.* 269: 1183-1190.
- Park, Y.K., et al. 1995. Osteocalcin expression in primary bone tumors—*in situ* hybridization and immunohistochemical study. *J. Korean Med. Sci.* 10: 263-268.
- Benayahu, D., et al. 1997. Osteocalcin (BGP), gene expression and protein production by marrow stromal adipocytes. *Biochem. Biophys. Res. Commun.* 231: 442-446.
- Colford, J., et al. 1997. Five osteocalcin assays compared: tracer specificity, fragment interference and calibration. *Clin. Chem.* 43: 1240-1241.
- Heikkinen, A.M., et al. 1997. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without Vitamin D3: a prospective, controlled, randomized study. *J. Clin. Endocrinol. Metab.* 82: 2476-2482.

## CHROMOSOMAL LOCATION

Genetic locus: BGLAP (human) mapping to 1q22.

## PRODUCT

osteocalcin siRNA (h) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu$ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see osteocalcin shRNA Plasmid (h): sc-40790-SH and osteocalcin shRNA (h) Lentiviral Particles: sc-40790-V as alternate gene silencing products.

## STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNase-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

## APPLICATIONS

osteocalcin siRNA (h) is recommended for the inhibition of osteocalcin expression in human cells.

## SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10  $\mu$ M in 66  $\mu$ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

## GENE EXPRESSION MONITORING

osteocalcin (G-5): sc-365797 is recommended as a control antibody for monitoring of osteocalcin gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG $\kappa$  BP-HRP: sc-516102 or m-IgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>TM</sup> Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgG $\kappa$  BP-FITC: sc-516140 or m-IgG $\kappa$  BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz<sup>®</sup> Mounting Medium: sc-24941 or UltraCruz<sup>®</sup> Hard-set Mounting Medium: sc-359850.

## RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor osteocalcin gene expression knockdown using RT-PCR Primer: osteocalcin (h)-PR: sc-40790-PR (20  $\mu$ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.